Side-by-side · Research reference

DSIPvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 3Reviewed8/39 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

DSIP

Thymosin α-1

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Thymosin α-1

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

—

Frequency

Once daily, pre-sleep

2× weekly (Mon/Thu typical)

Lower / starter dose

50 mcg pre-sleep

0.8 mg per injection

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

8–12 weeks per cycle

6–12 months for chronic indications

Reconstitution

Bacteriostatic water

Sterile water for injection per vial label

Timing

30–60 min pre-sleep

No specific time

Half-life

Short plasma; CNS effects last hours

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

04Side Effects & Safety

Parameter

DSIP

Thymosin α-1

Injection site reaction

Mild irritation

Erythema, mild discomfort

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

DSIP

Thymosin α-1

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

30–60 min pre-sleep.

2× weekly, e.g. Monday + Thursday.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

29–31G insulin syringe.

27–31G, 4–8 mm insulin syringe.